This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Avandia

GlaxoSmithKline plc

Drug Names(s): rosiglitazone, rosiglitazone XR

Description: Avandia (rosiglitazone), a member of the thiazolidinedione class of antidiabeticagents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highlyselective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARg). Activation of PPARg nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPARg-responsive genes also participate in the regulation of fatty acid metabolism.

Deal Structure: On 4/32/99, SmithKline Beecham entered into an agreement with Bristol-Myers Squibb to co-promote Avandia in the United States for the treatment of type 2 diabetes.

SmithKline Beecham will solely direct and fund all continuing development of Avandia.

Partners: Bristol-Myers Squibb Company


Avandia News

Pink Sheet Pharmacovigilance


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug